Sst2A IRS with the anti-sst2A antibody UMB-1 represents a valid tool in the clinical practice to identify acromegalic patients likely to be responders to adjuvant therapy with the currently available somatostatin analogs.
No takes yet. Share an insight, caveat, or question.
Gatto et al. (2012) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: